Traders should monitor for future disclosures on the valuation of this intellectual property, which could impact the balance sheet. The prior late filing and current IP clarification suggest governance and reporting risks that could affect investor confidence in this speculative, early-stage company.
Price Chart
Executive Summary
Quantum Genesis AI Corp. (formerly Quantumzyme Corp.) filed an amended 10-K/A to clarify intellectual property ownership, confirming a retroactive assignment of a patent application from its CEO to the company. This follows a prior late filing notice, indicating delayed financial reporting. No financial restatements were made.
Key Facts
- The amendment (10-K/A) clarifies that a patent application (US20250146029A1) for an ibuprofen-synthesis enzyme was initially filed in the CEO's personal name and has now been formally assigned to the company via a confirmatory agreement.
- The company previously filed an NT 10-K, indicating it could not file its annual report on time due to needing additional time to finalize financial statements.
- The amendment does not modify any financial statements, MD&A, or financial disclosures; it only updates Items 1, 1A, and 13 regarding IP and related-party transactions.
- The company has not recorded the intellectual property as a financial asset due to the lack of a formal valuation.
Financial Impact
No immediate financial impact. The IP was not recorded as an asset due to lack of valuation, and no financial statements were restated.
Risk Factors
- The prior late filing (NT 10-K) indicates potential weaknesses in financial reporting processes.
- The company's reliance on a single employee (CEO) and lack of formal agreements with third-party facilities pose operational risks.
- The company's financial status raises substantial doubt about its ability to continue as a going concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 10-K/A Filing (Primary) | 0001477932-26-002254 |
| Document: qtzm_ex311.htm | 0001477932-26-002254 |
| Document: qtzm_ex321.htm | 0001477932-26-002254 |
| Document: 0001477932-26-002254-index-headers.html | 0001477932-26-002254 |
| Document: 0001477932-26-002254-index.html | 0001477932-26-002254 |
| Document: 0001477932-26-002254.txt | 0001477932-26-002254 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 15, 2026 27w ago | 10-Q/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0300 (−85.71%) |
Apr 15, 2026 27w ago | 10-Q/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0300 (−85.71%) |
Apr 15, 2026 27w ago | 10-K/A | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0300 (−85.71%) |
Apr 15, 2026 27w ago | 8-K | $0.2100 $0.0850 | ▼ −59.52% | ▼ −65.57% | $0.0300 (−85.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers